You just read:

FDA Advisory Committee Unanimously Recommends Approval of Novartis Investigational Treatment FTY720 to Treat Relapsing Remitting MS

News provided by

Novartis Pharmaceuticals Corporation

Jun 10, 2010, 08:15 ET